CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial - Seite 6

Nachrichtenquelle: globenewswire
20.10.2020, 12:00  |  842   |   |   

Diesen Artikel teilen
Seite 6 von 5
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial - Seite 6 DSMC recommends CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint DSMC also requests another data review when enrollment reaches 293 patients (75%) to analyze all data, including …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel